United Therapeutics Corp. (UTHR) Ph3 Tyvaso Study May Be Groundbreaking - Jefferies
Tweet Send to a Friend
Jefferies analyst Eun Yang reiterated a Buy rating and $200.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
